Eledon Pharmaceuticals
Open
$3.58
Prev. Close
$3.58
High
$3.58
Low
$3.56
Market Snapshot
$270.79M
-3.4
-1.31
33
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company, which engages in development of therapies to protect transplanted organs and prevent rejection. The company is headquartered in Irvine, California and currently employs 33 full-time employees. The company went IPO on 2014-09-17. The firm is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company, which engages in development of therapies to protect transplanted organs and prevent rejection. The company is headquartered in Irvine, California and currently employs 33 full-time employees. The company went IPO on 2014-09-17. The firm is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
Recently from Cashu
Eledon Pharmaceuticals Expands Gene Therapy Pipeline for Autoimmune Diseases and Clinical Innovation
Eledon Pharmaceuticals Enhances Its Gene Therapy Pipeline Eledon Pharmaceuticals, a company specializing in gene therapies for the treatment of autoimmune diseases, announces a significant advancement…
Eledon Pharmaceuticals: Summary of Recent Developments and Stock Performance
To provide an accurate summary, I would need the specific text or article you would like me to summarize. Please provide the text so I can assist you effectively.
Eledon Pharmaceuticals: Key Developments and Future Outlook for Investors
Please provide the content you'd like summarized, and I'll be happy to assist you!
Eledon Pharmaceuticals: Summary Request for Content Not Provided.
I'm sorry, but it seems you haven't provided the text to summarize. Please share the relevant content about Eledon Pharmaceuticals, and I will assist you in creating the summary as requested.